Bluejay Diagnostics completes commercial-scale IL-6 antibody production

Bluejay Diagnostics (BJDX) completed commercial-scale production of both polyclonal and monoclonal antibodies targeting interleukin-6, a biomarker relevant to inflammatory and critical-care applications. The Company stated that both polyclonal and monoclonal antibodies met internal performance criteria, including reactivity, for use in Symphony cartridge manufacturing intended for clinical and potential future commercial applications. Bluejay has generated polyclonal antibodies using both third-party and internally developed immunogens. The Company intends to utilize antibodies produced from its proprietary immunogen for ongoing development activities in support of its intellectual-property strategy. The monoclonal antibodies produced by the Company, designated for use as detection antibodies in the IL-6 assay, have demonstrated acceptable binding, specificity, and signal performance characteristics for their intended diagnostic use, based on internal testing conducted to date. Based on current antibody inventory, Bluejay estimates that it has sufficient material to support production of more than nine million Symphony cartridges for clinical and commercial manufacturing purposes. The Company has also established the capability to produce additional antibodies as needed.